Diversified Trust Co Acquires 8,422 Shares of Gilead Sciences, Inc. $GILD

Diversified Trust Co lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 24.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 43,229 shares of the biopharmaceutical company’s stock after acquiring an additional 8,422 shares during the quarter. Diversified Trust Co’s holdings in Gilead Sciences were worth $4,798,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of GILD. GoalVest Advisory LLC boosted its holdings in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $27,000. Putney Financial Group LLC lifted its position in Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the period. Howard Hughes Medical Institute purchased a new stake in Gilead Sciences in the second quarter worth approximately $30,000. Finally, Kilter Group LLC bought a new stake in Gilead Sciences in the 2nd quarter worth approximately $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on GILD shares. Morgan Stanley increased their price target on Gilead Sciences from $147.00 to $151.00 and gave the company an “overweight” rating in a report on Friday, December 12th. BMO Capital Markets set a $135.00 price objective on Gilead Sciences in a research report on Tuesday, November 25th. Wolfe Research reissued an “outperform” rating and issued a $150.00 target price on shares of Gilead Sciences in a research report on Monday, December 15th. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Finally, Scotiabank assumed coverage on shares of Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $131.68.

Insider Activity

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of the stock in a transaction on Friday, November 28th. The stock was sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the sale, the director owned 1,339 shares in the company, valued at approximately $170,186.90. This represents a 67.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $122.00, for a total value of $366,000.00. Following the completion of the transaction, the chief financial officer owned 153,503 shares in the company, valued at $18,727,366. The trade was a 1.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 126,257 shares of company stock worth $15,606,892. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Up 0.2%

NASDAQ GILD opened at $124.91 on Tuesday. Gilead Sciences, Inc. has a 52 week low of $88.57 and a 52 week high of $128.70. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The company has a market capitalization of $154.97 billion, a P/E ratio of 19.37, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. The stock’s 50-day moving average price is $122.99 and its 200-day moving average price is $116.80.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm’s revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.